It has been over 15 years since any new drug for the treatment of Alzheimer’s has been approved – but a pair of relatively new biotechs focused on neurodegenerative diseases may be in the early stages of developing novel approaches to treat the disease, which currently afflicts 5.7 million Americans (and counting). For these two biotechs, which today’s article highlights as providing “investors with two avenues to get in on unique, cutting-edge research in Alzheimer’s disease”, CLICK HERE.